Adapted Boxing and Photography for Body Image in Haematology Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational program will measure changes in psychological well-being after a single adapted boxing session in patients with hematologic cancers. Researchers will use validated questionnaires to quantify body image and quality of life, including Rosenberg Self-Esteem Scale, QIC, and EORTC QLQ-C30, to provide objective data. The study relies on routine clinical care pathways and aims to quantify effects rather than establish causality. Data collection will occur in a Strasbourg haematology department setting where adapted physical activity is offered as part of standard care. Results will inform whether integrated physical activity approaches could benefit emotional well-being for this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients aged 18 or over
2. Patients diagnosed with cancer currently undergoing treatment in a haematology department (e.g. leukaemia, lymphoma, multiple myeloma, etc.), at various stages of their treatment journey
3. Patients considered sufficiently stable to undertake adapted physical activity following medical assessment (no medical contraindications to practising adapted boxing) and for whom it is offered as part of their standard care
4. Patients who have given their consent to participate in the study
5. Patients covered by a statutory health insurance scheme
6. Patients who have been prescribed adapted physical activity by a doctor

Exclusion Criteria:

1. Minors
2. Individuals subject to a court-ordered protective measure (judicial protection order, guardianship, curatorship, etc.)
3. Inability to provide the individual with informed consent (difficulties in understanding, insufficient command of French, etc.)
4. Patients with neurological or psychiatric disorders, including severe depression
5. Pregnant women (this criterion will be recorded based on the patient's statement)
6. Breastfeeding women

Where it's running

• Hôpital d'Hautepierre - CHRU Strasbourg
  Strasbourg, France Recruiting

Study contacts

• Study coordinator: Cécile SONNTAG, Doctor
• Email: cecile.sonntag@chru-strasbourg.fr
• Phone: +33 368767301

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using pulsed electromagnetic fields to prevent physical decline in hospitalized cancer patients

  This study is testing if pulsed electromagnetic fields can help hospitalized cancer patients maintain their physical strength and function while they are being treated.

  Recruiting National University Hospital, Singapore · Kent Ridge and 1 other locations · NCT06744764

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

• Capmatinib treatment for adults with cancers having MET gene changes

  This study is testing if capmatinib, a drug for lung cancer, can help adults with different types of cancers that have changes in the MET gene.

  Recruiting at 16 sites Phase 2/3 Cancer Research UK · Belfast and 16 other locations · NCT06988475

• Home management program for patients with blood cancers after chemotherapy

  This study tests a new home care program for patients with blood cancers after high-dose chemotherapy to see if it helps them recover better while allowing them to leave the hospital sooner.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bologna · NCT06814405

• Pharmacogenomics to improve voriconazole dosing for fungal infections

  This trial will test whether using a patient's CYP2C19 genotype with Bayesian dosing software helps get voriconazole levels into the therapeutic range by Day 8 for people with fungal infections, including those with blood cancers.

  Recruiting at 7 sites Phase 2 The University of Queensland · Seattle, Washington and 6 other locations · NCT06510699

• Combination of trastuzumab and pertuzumab for treating cancers with HER2 mutations

  This study is testing if a combination of two cancer drugs, trastuzumab and pertuzumab, can help adults and young people with cancers that have HER2 mutations or amplifications.

  Recruiting at 24 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT05786716

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.